Identifying populations sensitive to environmental chemicals by simulating toxicokinetic variability

Environment International

Volumn 106, Issue , 2017, Pages 105-118

  Ring, Caroline L ^a,b   Pearce, Robert G ^a,b   Setzer, R Woodrow ^b   Wetmore, Barbara A ^b,c   Wambaugh, John F ^b  

^a OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c ScitoVation LLC   (United States)

Author keywords

Environmental chemicals; High throughput; IVIVE; Risk assessment; Toxicokinetics

Indexed keywords

BIOHAZARDS; CHEMICAL HAZARDS; CHEMICALS; DIAGNOSIS; DISEASE CONTROL; HEALTH RISKS; PHYSIOLOGICAL MODELS; PHYSIOLOGY; RISK ASSESSMENT; TISSUE;

CENTERS FOR DISEASE CONTROL AND PREVENTIONS; ENVIRONMENTAL CHEMICALS; EQUIVALENT CONCENTRATIONS; HIGH THROUGHPUT; INDIVIDUAL VARIABILITY; IVIVE; PHYSIOLOGICAL PARAMETERS; TOXICOKINETICS;

POPULATION STATISTICS;

4,4' ISOPROPYLIDENEDIPHENOL; AZINPHOS METHYL; CARBOFURAN; CHLORPYRIFOS; CHLORPYRIFOS METHYL; COUMAFOS; DICROTOPHOS; DIMETHOATE; DIMPYLATE; ENVIRONMENTAL CHEMICAL; ETHION; FENITROTHION; FENTHION; FLUORENE; LINDANE; MALATHION; METHIDATHION; METHYL PARABEN; NAPHTHALENE; PARATHION; PARATHION METHYL; PERMETHRIN; PHORATE; PHOSMET; PHTHALIC ACID DIBUTYL ESTER; PHTHALIC ACID DIETHYL ESTER; PHTHALIC ACID DIOCTYL ESTER; QUINTOZENE; TRICLOSAN; UNINDEXED DRUG;

CHEMICAL ANALYSIS; CONCENTRATION (COMPOSITION); ENVIRONMENTAL FACTOR; HEALTH RISK; IDENTIFICATION METHOD; MONTE CARLO ANALYSIS; REACTION KINETICS; RESEARCH WORK; RISK ASSESSMENT; TOXICOLOGY;

ARTICLE; CONTROLLED STUDY; HEALTH HAZARD; IN VITRO STUDY; MATHEMATICAL MODEL; MONTE CARLO METHOD; POPULATION MODEL; POPULATION RISK; PRIORITY JOURNAL; TOXICOKINETICS; UNITED STATES; VULNERABLE POPULATION; ADOLESCENT; ADULT; AGED; CHILD; DEMOGRAPHY; DOSE RESPONSE; ENVIRONMENTAL MONITORING; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; MALE; MIDDLE AGED; NUTRITION; POLLUTANT; RISK ASSESSMENT; TOXICITY; YOUNG ADULT;

UNITED STATES;

ADOLESCENT; ADULT; AGED; CHILD; DEMOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL MONITORING; ENVIRONMENTAL POLLUTANTS; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MALE; MIDDLE AGED; MONTE CARLO METHOD; NUTRITION SURVEYS; RISK ASSESSMENT; TOXICOKINETICS; UNITED STATES; YOUNG ADULT;

EID: 85020770832     PISSN: 01604120     EISSN: 18736750     Source Type: Journal    
DOI: 10.1016/j.envint.2017.06.004     Document Type: Article

References (84)

1. Abdo, N., Xia, M., Brown, C.C., Kosyk, O., Huang, R., Sakamuru, S. et al., Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ. Health Perspect., 123, 2015, 458.
2. Aylward, L.L., Hays, S.M., Consideration of dosimetry in evaluation of ToxCast™ data. J. Appl. Toxicol. 31 (2011), 741–751.
3. Barter, Z.E., Bayliss, M.K., Beaune, P.H., Boobis, A.R., Carlile, D.J., Edwards, R.J. et al., Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human micro-somal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8 (2007), 33–45.
4. Barter, Z.E., Chowdry, J.E., Harlow, J.R., Snawder, J.E., Lipscomb, J.C., Rostami-Hodjegan, A., Covariation of human microsomal protein per gram of liver with age: absence of influence of operator and sample storage may justify interlaboratory data pooling. Drug Metab. Dispos. 36 (2008), 2405–2409.
5. Baxter-Jones, A.D., Faulkner, R.A., Forwood, M.R., Mirwald, R.L., Bailey, D.A., Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J. Bone Miner. Res. 26 (2011), 1729–1739.
6. Belle, D.J., Singh, H., Genetic factors in drug metabolism. Am. Fam. Physician, 77, 2008.
7. Bernard, S., Neville, K.A., Nguyen, A.T., Flockhart, D.A., Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 11 (2006), 126–135.
8. Birnbaum, L., Bischoff, K., Blancato, J., Clewell, H., Dedrick, R., Delp, M. et al., Physiological Parameter Values for PBPK Models. 1994, International Life Sciences Institute Risk Sciences Institute.
9. Bosgra, S., van Eijkeren, J., Bos, P., Zeilmaker, M., Slob, W., An improved model to predict physiologically based model parameters and their inter-individual variability from anthropometry. Crit. Rev. Toxicol. 42 (2012), 751–767.
10. Chiba, K., Kato, M., Ito, T., Suwa, T., Sugiyama, Y., Inter-individual variability of in vivo CYP2D6 activity in different genotypes. Drug Metab. Pharmacokinet. 27 (2012), 405–413.
11. Chiba, K., Shimizu, K., Kato, M., Nishibayashi, T., Terada, K., Izumo, N. et al., Prediction of inter-individual variability in the pharmacokinetics of CYP2C19 substrates in humans. Drug Metab. Pharmacokinet. 29 (2014), 379–386.
12. Cubitt, H.E., Rowland-Yeo, K., Howgate, E.M., Rostami-Hodjegan, A., Barter, Z.E., Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41 (2011), 623–638.
13. Ginsberg, G., Hattis, D., Sonawane, B., Russ, A., Banati, P., Kozlak, M. et al., Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol. Sci. 66 (2002), 185–200.
14. Ginsberg, G., Slikker, W., Bruckner, J., Sonawane, B., Incorporating Children's Toxicokinetics into a risk framework. Environ. Health Perspect. 112 (2003), 272–283.
15. Ginsberg, G., Hattis, D., Russ, A., Sonawane, B., Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals. Environ. Health Perspect., 2005, 1243–1249.
16. Glen, G., Isaacs, K., Estimating Sobol sensitivity indices using correlations. Environ. Model Softw. 37 (2012), 157–166.
17. Grummer-Strawn, L.M., Reinold, C.M., Krebs, N.F., Control, C.f.D.; Prevention, Use of World Health Organization and CDC Growth Charts for Children Aged 0–59 Months in the United States. 2010, Department of Health and Human Services, Centers for Disease Control and Prevention.
18. Haycock, G.B., Schwartz, G.J., Wisotsky, D.H., Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults. J. Pediatr. 93 (1978), 62–66.
19. Hines, R.N., Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol. 21 (2007), 169–175.
20. Hiratsuka, M., In vitro assessment of the allelic variants of cytochrome P450. Drug Metab. Pharmacokinet. 27 (2012), 68–84.
21. Howgate, E., Rowland-Yeo, K., Proctor, N., Tucker, G., Rostami-Hodjegan, A., Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica 36 (2006), 473–497.
22. Inoue, S., Howgate, E., Rowland-Yeo, K., Shimada, T., Yamazaki, H., Tucker, G. et al., Prediction of in vivo drug clearance from in vitro data. II: potential inter-ethnic differences. Xenobiotica 36 (2006), 499–513.
23. Israili, Z., Dayton, P., Human alpha-1-glycoprotein and its interations with drugs. Drug Metab. Rev. 33 (2001), 161–235.
24. Jacques, J., Lavergne, C., Devictor, N., Sensitivity analysis in presence of model uncertainty and correlated inputs. Reliab. Eng. Syst. Saf. 91 (2006), 1126–1134.
25. Jamei, M., Dickinson, G.L., Rostami-Hodjegan, A., A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of ‘bottom-up'vs ‘top-down'recognition of covariates. Drug Metab. Pharmacokinet. 24 (2009), 53–75.
26. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., Rostami-Hodjegan, A., The Simcyp® population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5 (2009), 211–223.
27. Johnson, T.N., Rostami-Hodjegan, A., Tucker, G.T., Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin. Pharmacokinet. 45 (2006), 931–956.
28. Johnson, C.L., Paulose-Ram, R., Ogden, C.L., Carroll, M.D., Kruszon-Moran, D., Dohrmann, S.M. et al., National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital and health statistics Series 2. Data Eval. Methods Res., 2013, 1–24.
29. Johnson, C.L., Dohrmann, S.M., Burt, V.L., Mohadjer, L.K., National health and nutrition examination survey: sample design, 2011-2014. Vital and health statistics Series 2. Data Eval. Methods Res., 2014, 1–33.
30. Judson, R.S., Kavlock, R.J., Setzer, R.W., Cohen Hubal, E.A., Martin, M.T., Knudsen, T.B. et al., Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol. 24 (2011), 451–462.
31. Kato, M., Chiba, K., Ito, T., Koue, T., Sugiyama, Y., Prediction of interindividual variability in pharmacokinetics for CYP3A4 substrates in humans. Drug Metab. Pharmacokinet. 25 (2010), 367–378.
32. Kavlock, R., Chandler, K., Houck, K., Hunter, S., Judson, R., Kleinstreuer, N. et al., Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem. Res. Toxicol. 25 (2012), 1287–1302.
33. Kedderis, G.L., Lipscomb, J.C., Application of in vitro biotransformation data and pharmacokinetic modeling to risk assessment. Toxicol. Ind. Health 17 (2001), 315–321.
34. Koo, W.W., Walters, J.C., Hockman, E.M., Body composition in human infants at birth and postnatally. J. Nutr. 130 (2000), 2188–2194.
35. Kuczmarski, R.J., Ogden, C.L., Guo, S.S., Grummer-Strawn, L.M., Flegal, K.M., Mei, Z. et al., 2000 CDC growth charts for the United States: methods and development. Vital Health Stat. Series 11, Data from the national health survey 246 (2002), 1–190.
36. Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Y.L., Castro, A.F., Feldman, H.I. et al., A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150 (2009), 604–612.
37. Lipscomb, J.C., Kedderis, G.L., Incorporating human interindividual biotransformation variance in health risk assessment. Sci. Total Environ. 288 (2002), 13–21.
38. Lipscomb, J.C., Teuschler, L.K., Swartout, J.C., Striley, C.A., Snawder, J.E., Variance of microsomal protein and cytochrome P450 2E1 and 3A forms in adult human liver. Toxicol. Mech. Methods 13 (2003), 45–51.
39. Looker, A., Borrud, L., Hughes, J., Fan, B., Shepherd, J., Sherman, M., Total body bone area, bone mineral content, and bone mineral density for individuals aged 8 years and over: United States, 1999-2006. Vital and health statistics Series 11, Data from the National Health Survey, 2013, 1–78.
40. Lubin, B., Reference values in infancy and childhood. Nathan, D., Oski, F., (eds.) Hematology of Infancy and Childhood, 1987.
41. Lumley, T., Analysis of complex survey samples. J. Stat. Softw. 9 (2004), 1–19.
42. Luo, H.R., Poland, R.E., Lin, K.M., Wan, Y.J.Y., Genetic polymorphism of cytochrome P450 2C19 in Mexican Americans: a cross-ethnic comparative study. Clin. Pharmacol. Ther. 80 (2006), 33–40.
43. Ma, M.K., Woo, M.H., Mcleod, H.L., Genetic basis of drug metabolism. Am. J. Health Syst. Pharm. 59 (2002), 2061–2069.
44. McNally, K., Cotton, R., Hogg, A., Loizou, G., PopGen: a virtual human population generator. Toxicology 315 (2014), 70–85.
45. Mizutani, T., PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 35 (2003), 99–106.
46. Obach, R.S., Lombardo, F., Waters, N.J., Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug Metab. Dispos. 36 (2008), 1385–1405.
47. Ogden, C.L., Carroll, M.D., Kit, B.K., Flegal, K.M., Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 311 (2014), 806–814.
48. Ogiu, N., Nakamura, Y., Ijiri, I., Hiraiwa, K., Ogiu, T., A statistical analysis of the internal organ weights of normal Japanese people. Health Phys. 72 (1997), 368–383.
49. Park, Y.H., Lee, K., Soltow, Q.A., Strobel, F.H., Brigham, K.L., Parker, R.E. et al., High-performance metabolic profiling of plasma from seven mammalian species for simultaneous environmental chemical surveillance and bioeffect monitoring. Toxicology 295 (2012), 47–55.
50. Pearce, R., Strope, C., Setzer, R.W., Sipes, N., Wambaugh, J.F., httk: R package for high-throughput toxicokinetics. J. Stat. Softw., 2016 (in press).
51. Price, P., Instructions for Use of Software Physiological Parameters for PBPK Modeling Version 1.3 (P3MTM 1.3). 2003.
52. Price, P.S., Conolly, R.B., Chaisson, C.F., Gross, E.A., Young, J.S., Mathis, E.T. et al., Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit. Rev. Toxicol. 33 (2003), 469–503.
53. Rager, J.E., Strynar, M.J., Liang, S., McMahen, R.L., Richard, A.M., Grulke, C.M. et al., Linking high resolution mass spectrometry data with exposure and toxicity forecasts to advance high-throughput environmental monitoring. Environ. Int. 88 (2016), 269–280.
54. Rotroff, D.M., Wetmore, B.A., Dix, D.J., Ferguson, S.S., Clewell, H.J., Houck, K.A. et al., Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 117 (2010), 348–358.
55. Routledge, P., The plasma protein binding of basic drugs. Br. J. Clin. Pharmacol. 22 (1986), 499–506.
56. Saltelli, A., Annoni, P., Azzini, I., Campolongo, F., Ratto, M., Tarantola, S., Variance based sensitivity analysis of model output. Design and estimator for the total sensitivity index. Comput. Phys. Commun. 181 (2010), 259–270.
57. Schmitt, W., General approach for the calculation of tissue to plasma partition coefficients. Toxicol. in Vitro 22 (2008), 457–467.
58. Schwartz, G.J., Work, D.F., Measurement and estimation of GFR in children and adolescents. Clin. J. Am. Soc. Nephrol. 4 (2009), 1832–1843.
59. Sohlenius-Sternbeck, A.-K., Afzelius, L., Prusis, P., Neelissen, J., Hoogstraate, J., Johansson, J. et al., Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40 (2010), 637–649.
60. Strom, C.M., Goos, D., Crossley, B., Zhang, K., Buller-Burkle, A., Jarvis, M. et al., Testing for variants in CYP2C19: population frequencies and testing experience in a clinical laboratory. Genet. Med. 14 (2011), 95–100.
61. Strope, C.L., Mansouri, K., Kancherla, J., Stevens, C., Wambaugh, J.F., High-Throughput Pharmacokinetic Modeling Using Computationally Predicted Parameter Values: Dissociation Constants. 2015, Society of Toxicology Annual Meeting, San Diego, CA.
62. Tan, Y.-M., Liao, K.H., Conolly, R.B., Blount, B.C., Mason, A.M., Clewell, H.J., Use of a physiologically based pharmacokinetic model to identify exposures consistent with human biomonitoring data for chloroform. J. Toxic. Environ. Health A 69 (2006), 1727–1756.
63. Tan, Y.-M., Liao, K.H., Clewell, H.J., Reverse dosimetry: interpreting trihalomethanes biomonitoring data using physiologically based pharmacokinetic modeling. J. Expo. Sci. Environ. Epidemiol. 17 (2007), 591–603.
64. Thomas, R.S., Philbert, M.A., Auerbach, S.S., Wetmore, B.A., Devito, M.J., Cote, I. et al., Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol. Sci. 136 (2013), 4–18.
65. Tonnelier, A., Coecke, S., Zaldívar, J.-M., Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Arch. Toxicol. 86 (2012), 393–403.
66. USEPA, Integrated Bioactivity and Exposure Ranking: A Computational Approach for the Prioritization and Screening of Chemicals in the Endocrine Disruptor Screening Program. 2014.
67. USEPA, EPI (Estimation Programs Interface) Suite. 2015.
68. USGAO, Office U.S.G.A., (eds.) Toxic Substances: EPA Has Increased Efforts to Assess and Control Chemicals but Could Strengthen Its Approach, 2013.
69. Valentin, J., Basic anatomical and physiological data for use in radiological protection: reference values: ICRP publication 89. Ann. ICRP 32 (2002), 1–277.
70. Verbraecken, J., Van de Heyning, P., De Backer, W., Van Gaal, L., Body surface area in normal-weight, overweight, and obese adults. A comparison study. Metabolism 55 (2006), 515–524.
71. Wambaugh, J.F., Setzer, R.W., Reif, D.M., Gangwal, S., Mitchell-Blackwood, J., Arnot, J.A. et al., High-throughput models for exposure-based chemical prioritization in the ExpoCast project. Environ. Sci. Technol. 47 (2013), 8479–8488.
72. Wambaugh, J.F., Wang, A., Dionisio, K.L., Frame, A., Egeghy, P., Judson, R. et al., High throughput heuristics for prioritizing human exposure to environmental chemicals. Environ. Sci. Technol. 48 (2014), 12760–12767.
73. Wambaugh, J.F., Wetmore, B.A., Pearce, R., Strope, C., Goldsmith, R., Sluka, J.P. et al., Toxicokinetic triage for environmental chemicals. Toxicol. Sci. 147 (2015), 55–67.
74. Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K., Thornton, S.J., Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nat. Rev. Drug Discov. 7 (2008), 84–99.
75. Webber, C.E., Barr, R.D., Age-and gender-dependent values of skeletal muscle mass in healthy children and adolescents. J. Cachex. Sarcopenia Muscle 3 (2012), 25–29.
76. Wetmore, B.A., Wambaugh, J.F., Ferguson, S.S., Sochaski, M.A., Rotroff, D.M., Freeman, K. et al., Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 125 (2012), 157–174.
77. Wetmore, B.A., Allen, B., Clewell, H.J. 3rd, Parker, T., Wambaugh, J.F., Almond, L.M. et al., Incorporating population variability and susceptible subpopulations into dosimetry for high-throughput toxicity testing. Toxicol. Sci. 142 (2014), 210–224.
78. Wetmore, B.A., Wambaugh, J.F., Allen, B., Ferguson, S.S., Sochaski, M.A., Setzer, R.W. et al., Incorporating high-throughput exposure predictions with Dosimetry-adjusted in vitro bioactivity to inform chemical toxicity testing. Toxicol. Sci. 148 (2015), 121–136.
79. WHO, WHO D.o.N.f.H.a.D., (eds.) WHO Child Growth Standards: Length/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for-Age: Methods and Development, 2006.
80. WHO, (WHO) W.H.O., (eds.) WHO Anthro for Personal Computers Manual: Software for Assessing Growth and Development of the World's Children, Version 3.2.2, 2011, 2010, WHO, Geneva.
81. Wilkinson, G.R., Shand, D.G., Commentary: a physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 18 (1975), 377–390.
82. Willmann, S., Höhn, K., Edginton, A., Sevestre, M., Solodenko, J., Weiss, W. et al., Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J. Pharmacokinet. Pharmacodyn. 34 (2007), 401–431.
83. Yasuda, S.U., Zhang, L., Huang, S.M., The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin. Pharmacol. Ther. 84 (2008), 417–423.
84. Yeo, K.R., Rostami-Hodjegan, A., Tucker, G., Abundance of cytochromes P450 in human liver. Br. J. Clin. Pharmacol. 57 (2004), 687–688.